BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation (BeEAC-1)

Clinical Trial ID NCT03315520

Rank	Title	Journal	Year	PubWeight™‹?›
1	Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.	Lancet	2002	3.50
2	Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.	J Clin Oncol	2008	2.32
3	The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.	Blood	1998	1.49
4	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.	Blood	2011	1.35
5	Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.	J Clin Oncol	2012	1.13
6	Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.	Br J Haematol	2012	0.95
7	Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.	Biol Blood Marrow Transplant	2015	0.88
8	Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.	Expert Opin Investig Drugs	2013	0.78